Laxxon has received a grant by Freistaat Thüringen and the ESF Plus (European Social Fund) for the further development of LXM.2.

Laxxon's New Generation Levodopa/Carbidopa for Parkinson's Disease project, LXM.5, has been awarded a grant.

[New York, New York] – Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced drug delivery...

[New York, New York] – Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug...

New independent directors Christof Bircher and Nneka Ukpai bring significant expertise in business strategy, corporate finance and...

NEW YORK, NY / ACCESSWIRE / January 7, 2024 /  Laxxon Medical, a leading pharma-technology company pioneering a new generation of...

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Laxxon Medical Corp., a leading pharma technology platform company focusing on oral drug...

Laxxon is seeking out-licensing opportunities for lead asset LXM.2, or co-developments projects with 3DSP platform technology SPID® at...

NEW YORK, NY / ACCESSWIRE / October 9, 2024 /  Laxxon Medical , a US-based pharma-technology company pioneering a new generation of...

The cooperation between Laxxon and Adare enables the clinical and commercial production of advanced drug delivery systems at Adare’s cGMP fa